Book contents
- Frontmatter
- Contents
- Preface to the seventh edition
- List of contributors
- List of abbreviations
- 1 Basic principles
- 2 Cell culture techniques
- 3 Centrifugation
- 4 Microscopy
- 5 Molecular biology, bioinformatics and basic techniques
- 6 Recombinant DNA and genetic analysis
- 7 Immunochemical techniques
- 8 Protein structure, purification, characterisation and function analysis
- 9 Mass spectrometric techniques
- 10 Electrophoretic techniques
- 11 Chromatographic techniques
- 12 Spectroscopic techniques: I Spectrophotometric techniques
- 13 Spectroscopic techniques: II Structure and interactions
- 14 Radioisotope techniques
- 15 Enzymes
- 16 Principles of clinical biochemistry
- 17 Cell membrane receptors and cell signalling
- 18 Drug discovery and development
- Index
- Plate section
- References
This chapter is part of a book that is no longer available to purchase from Cambridge Core
18 - Drug discovery and development
By
Book contents
- Frontmatter
- Contents
- Preface to the seventh edition
- List of contributors
- List of abbreviations
- 1 Basic principles
- 2 Cell culture techniques
- 3 Centrifugation
- 4 Microscopy
- 5 Molecular biology, bioinformatics and basic techniques
- 6 Recombinant DNA and genetic analysis
- 7 Immunochemical techniques
- 8 Protein structure, purification, characterisation and function analysis
- 9 Mass spectrometric techniques
- 10 Electrophoretic techniques
- 11 Chromatographic techniques
- 12 Spectroscopic techniques: I Spectrophotometric techniques
- 13 Spectroscopic techniques: II Structure and interactions
- 14 Radioisotope techniques
- 15 Enzymes
- 16 Principles of clinical biochemistry
- 17 Cell membrane receptors and cell signalling
- 18 Drug discovery and development
- Index
- Plate section
- References
Summary
HUMAN DISEASE AND DRUG THERAPY
Human disease
The wide range of diseases to which humans are exposed have in common the fact that each is the result of either some physiological dysfunction caused by a gene mutation or incorrect expression of the related protein, or of the exposure of the individual to an environmental factor, such as pesticides, diet, or bacterial, fungal or viral infection. The dysfunction gives rise to characteristic medical symptoms that enable the condition to be diagnosed, commonly by diagnostic tests of the type described in Chapter 16, and an evaluation made of the severity of the condition and the future prospects of the patient making a full recovery from it. Underlying many of the conditions at a molecular level is a change in the amount, function or activity of one or more proteins that in turn trigger changes in cellular, tissue or organ function. A large part of current worldwide medical research is aimed at the elucidation of the molecular mechanisms underlying diseases such as the various forms of cancer and neurological conditions such as Parkinson's disease, motor neurone disease and multiple sclerosis, in order to identify key proteins involved in the disease process with a view to selecting one of the proteins as a target for the development of a new drug and thereby to minimise or eliminate the symptoms.
Information
- Type
- Chapter
- Information
- Principles and Techniques of Biochemistry and Molecular Biology , pp. 709 - 735Publisher: Cambridge University PressPrint publication year: 2010
References
(2007). Guidelines on the Practice of Ethics Committees in Medical Research with Human Participants, 4th edn. London: Royal College of Physicians.
(ed.) (2008). Antisense Drug Technology: Principles, Strategies and Applications, 2nd edn. New York: CRC Press. (Gives a review of the mechanisms of action, pharmacokinetics and therapeutic potential of antisense drugs in the context of a wide range of clinical conditions.)Google Scholar
(ed.) (2008). High-Throughput Lead Optimization in Drug Discovery. New York: CRC Press. (Uses real examples to illustrate the application of the technique in modern drug development.)CrossRefGoogle Scholar
(ed.) (2006). Drug Discovery and Development: Technology in Transition. London: Elsevier. (An in-depth coverage written in an authoritative style by experts from the pharmaceutical industry.)Google Scholar
and (2000). A commentary on the use of hepatocytes in drug metabolism studies during drug discovery. Drug Metabolism Reviews, 32, 219–240.CrossRefGoogle ScholarPubMed
, , , and (2008). Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nature Reviews Drug Discovery, 7, 818–826.CrossRefGoogle ScholarPubMed
, and (2007). In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British Journal of Pharmacology, 152, 9–20.CrossRefGoogle ScholarPubMed
and (2007). Modern analytical approaches to high-throughput drug discovery. Trends in Analytical Chemistry, 26, 171–180.CrossRefGoogle Scholar
, and (2006). Drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery, 5, 821–832.CrossRefGoogle ScholarPubMed
and (2008). Is raising HDL a futile strategy for atheroprotection?Nature Reviews Drug Discovery, 7, 143–154.CrossRefGoogle ScholarPubMed
(2008). Trends in disease focus of drug development. Nature Reviews Drug Discovery, 7, 639–640.CrossRefGoogle ScholarPubMed
and (2008). Structural diversity of G-protein coupled receptors and significance for drug discovery. Nature Reviews Drug Discovery, 7, 339–357.CrossRefGoogle ScholarPubMed
and (2008). Form to function: current and future roles for atherosclerosis imaging in drug discovery. Nature Reviews Drug Discovery, 7, 517–530.CrossRefGoogle Scholar
, and (2008). Tetherin inhibits retrovirus release and is antagonised by HIV-1 Vpu. Nature, 451, 425–431.CrossRefGoogle Scholar
and (2008). Translating molecular discoveries into new therapies for atherosclerosis. Nature, 451, 904–912.CrossRefGoogle ScholarPubMed
(2007). Chemogenomic approaches to rational drug design. British Journal of Pharmacology, 152, 38–52.CrossRefGoogle ScholarPubMed
(2008). Pharmacogenetics in drug discovery and development: a translational perspective. Nature Reviews Drug Discovery, 7, 807–817.CrossRefGoogle Scholar
and (2007). The potential of high-content high-throughput microscopy in drug discovery. British Journal of Pharmacology, 152, 62–71.CrossRefGoogle ScholarPubMed
, and (2008). Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine, 14, 32–44.CrossRefGoogle ScholarPubMed
Accessibility standard: Unknown
Accessibility compliance for the PDF of this book is currently unknown
and may be updated in the future.